Rising Occurrence Of Genetic Abnormalities Fuels Hemophilia Market Growth: Strengthening the Growth Trajectory of the Hemophilia Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Is the Expected CAGR for the Hemophilia Market Through 2025?
In recent times, there has been a significant expansion in the hemophilia market. The market, which stood at $13.83 billion in 2024, is projected to inflate to $15.13 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 9.4%. The expansion during the historic period can be credited to government policies, an escalation in the count of hemophilia patients, an augmentation in diagnostic screening, and a surge in awareness regarding hemophilia treatments.

What's the Projected Size of the Global Hemophilia Market by 2029?
In the coming years, the hemophilia market is projected to experience significant expansion. Its size will reach $21.28 billion in 2029, climbing at a compound annual growth rate (CAGR) of 8.9%. The robust growth over the forecast period can be attributed to factors such as the rising hemophilia related research and development initiatives, increased diagnostic screenings, stepped up healthcare expenditure, and widespread access to treatments. Key trends for this period also include the introduction and authorization of new drugs, acceleration in the development of novel medications, increasing research and clinical trials, the emergence of digital health solutions and advancements in treatment options.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Top Growth Drivers in the Hemophilia Industry: What's Accelerating the Market?
The surge in cases of genetic abnormalities is anticipated to provide impetus to the progression of the hemophilia market. Genetic abnormalities, sometimes referred to as genetic deviations or genetic disorders, are alterations in an individual's genetic material that can lead to diverse health complications and physical characteristics. The purpose of hemophilia treatment is to manage or reign in situations of hemorrhage, downsize sequela, and enhance life quality for those bearing genetic abnormalities. For instance, in June 2023, according to Gene People, a UK-based charity organization lending support to genetic disorders, one of every 25 children had a genetic disorder. As a result, 30,000 fledglings and juveniles in the UK and well above 2.4 million juveniles and grown-ups are affected annually by a genetic aberration. Thus, the escalation in the frequency of genetic disorders is fueling the advancement of the hemophilia market. It is anticipated that increasing endeavors towards investment in hemophilia care will facilitate the progress of the hemophilia market. These investment endeavors include the channelization of monetary assets, programming in research and development, as well as enhancements in healthcare infrastructures fundamentally to further the treatment and management and promote the overall good health of hemophilia patients. These efforts are aimed at boosting access to hemophilia treatment in growth regions by harnessing initiatives and collaborations that amplify the patient index and the market size. As an instance, in September 2022, the National Hemophilia Foundation (NHF), a nonprofit body based in the US, brought forth Pathway to Cures (P2C), a new-age philanthropic investment fund with a pioneering fund value of $3.5 million. The purpose of P2C is to facilitate major and transformative progress in the area of inheritable blood maladies by utilizing its team's proficiency in blood disorder research and capitalizing on the benefits of NHF's rich connect with scientific research institutions and expert clinicians. Hence, increasing investment efforts in hemophilia care will impel the growth of the hemophilia market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12905&type=smp

What Trends Will Shape the Hemophilia Market Through 2029 and Beyond?
Key players in the hemophilia industry are striving to solidify their market standing by developing innovative treatments such as ALTUVIIIO. Sanofi S.A., a pharmaceutical and healthcare company originating from France, introduced ALTUVIIIO for hemophilia in February 2023, gaining approval from The Food and Drug Administration (FDA), a governmental agency in the US. ALTUVIIIO, which is administered once a week, is the only medication available for hemophilia A that regularly provides near-normal factor activity levels (above 40%) throughout most of the week and significantly reduces bleeding as compared to previous factor VIII prophylaxis.

What Are the Main Segments in the Hemophilia Market?
The hemophilia market covered in this report is segmented -

1) By Type: Hemophilia A, Hemophilia B, Hemophilia C, Other Types
2) By Treatment: Replacement Therapy, Hemostatic Agents, Desmopressin, Gene Therapy, Other Treatments
3) By End-User: Hospitals, Clinics, Home Care Settings, Other End-Users

Subsegments:
1) By Hemophilia A: Severe Hemophilia A, Moderate Hemophilia A, Mild Hemophilia A
2) By Hemophilia B: Severe Hemophilia B, Moderate Hemophilia B, Mild Hemophilia B
3) By Hemophilia C: Severe Hemophilia C, Mild Hemophilia C
4) By Other Types: Acquired Hemophilia, Von Willebrand Disease

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12905&type=smp

Which Top Companies are Driving Growth in the Hemophilia Market?
Major companies operating in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Precision BioLogic Inc., Dimension Therapeutics, Chameleon Biosciences, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB.

Which Regions Will Dominate the Hemophilia Market Through 2029?
North America was the largest region in the hemophilia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hemophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12905

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.